Edema in the eye

This information is intended for specialists in the field of public health and pharmaceuticals. Patients should not use this information as medical advice or advice.

The most common cause of so-calledcatarrhal diseases, which the average person suffers twice a year, are acute respiratory viral infections (ARVI). The use of antihistamines I generation in ARVI can reduce the severity of nasal mucosa edema, rhinorrhea, sneezing, and also alleviate the severity of the course of the disease. At the same time, antihistamines do not affect the degree and severity of the immune response and, therefore, do not interfere with the body's ability to fight infection.

A typical manifestation of the body's reaction in the development of acute respiratory viral infection is rhinitis, an inflammation of the nasal mucosa, characterized by symptoms such as nasal congestion, rhinorrhea, sneezing, and itching in the nose.

With a sharp symptomatology of acute rhinitisthe general well-being of the patient worsens, the working capacity decreases, the quality of life decreases. Because of the edema of the mucous membrane of the paranasal sinuses, there is a headache in the forehead area, a feeling of stuffiness in the ears. In this case, there is a threat of complications. It is the probability of the transition of the process into a chronic form and the development of complications that determines the appropriateness of using antihistamines in acute rhinitis. Their use contributes to the elimination of many symptoms of acute respiratory viral infection, which minimizes the intake of "cold" medications (eg, vasoconstrictive intranasal sprays and drops).

Antihistamines are medicinaldrugs commonly used to treat allergies. It is believed that the advisability of using antihistamines in ARI is due to the fact that many of the manifestations of acute respiratory viral infection are similar to those of allergic rhinitis.

The mechanism of action of antihistaminesis associated with blockade of H1-receptors. In addition, anti-histamine preparations of the first generation, in contrast to the preparations of the second generation, penetrate the blood-brain barrier, and also block M-cholinergic receptors, which suppresses sneezing and coughing and "drying" of the mucous membranes, in addition, the antitrositonin effect of these drugs has been proved. in turn, reduces the permeability of the walls of the vessels, thereby reducing the severity of the symptoms of intoxication and the release of mucus from the nasal cavity. A number of studies have shown that it is due to anticholinergic action that antihistamines of the first generation (for example, klemastine fumarate, chloropyramine) are able to reduce the symptoms of rhinitis in ARVI (sneezing, swelling of the nasal mucosa) and the overall severity of the disease. However, antihistamines of the second generation are not able to reduce sneezing in ARVI.

Antihistamines of the first generation (klemastinafumarate) are highly effective drugs and can be recommended for symptomatic and pathogenetic therapy of rhinitis in ARVI. Clemastine fumarate is a fairly safe and effective drug when used in both adults and children. In adults, the optimal effect is achieved with the use of the drug 2 tablets per night. Thus, the severity of the sedative effect decreases, plus a dosage of 2 mg persists for about 24-36 hours, which allows for 2 days to reach a constant concentration of the drug in the blood. In children, the optimal dosage is from 0.5 to 1 mg twice a day.

The article was published in the newspaper "Pharmaceutical Gazette"